The Rare-Earths Problem Inside the Medicine Cabinet

A supply chain rarely breaks at the rung you can see. The drug industry is learning this the way the electronics industry learned it with rare earths: the choke point sits one layer below the layer governments talk about. When the layer above looks like a generic commodity, the layer below is almost always concentrated in one country, and almost always unpriced.

SCMP's data, drawn from Chinese government figures, puts the visible rung at 40 per cent: that share of the world's active pharmaceutical ingredients, the chemicals that give medicines their effect, now comes from China. Brookings' March testimony named the rung beneath: nearly 41 per cent of key starting materials for drugs approved in the United States are sourced exclusively from China. APIs are the molecules. KSMs are the feedstock. The KSMs are where the leverage lives.

CFR warned last month that the parallel to rare earths is real, and the Atlantic Council answered with a policy frame: coordinated resilience across the United States, the European Union, India and Mexico. ITIF's testimony today called the problem whole-of-government. The fix is not one country rebuilding one factory. It is a four-country chemistries pact aimed at the layer nobody photographs.

The medicine cabinet runs on a chemistry layer most procurement teams never audit. The bottleneck is not the pill.